NYSE:JNJPharmaceuticals
Should J&J’s Talc Verdict and Mounting Lawsuits Prompt Reassessment From Johnson & Johnson (JNJ) Investors?
In February 2026, a Philadelphia jury found Johnson & Johnson liable for its talc-based baby powder contributing to a woman’s ovarian cancer death, awarding US$50,000 in compensatory and US$200,000 in punitive damages amid more than 70,000 similar lawsuits pending nationwide.
This verdict, alongside recent scientific findings strengthening the evidence of a link between genital talc use and ovarian cancer, intensifies Johnson & Johnson’s legal and reputational risk at a time when it has...